Rosetta Genomics (ROSG-OLD -3.6%) slips after Sidoti cut the shares to Neutral earlier today. The stock has essentially been dead money since last November, trading in a narrow range between $4 - $5 after cratering off a $23 higher earlier in the year. Just yesterday, Aegis cut its price target on the stock as well. On the surface, that may not seem too significant, but it's worth noting that Aegis has acted as the placement agent for the last four of ROSG-OLD’s public offerings.